Brief: MorphoSys: Preliminary 2022 Monjuvi U.S. Net Product Sales Of $89.4 Mln

Morphosys AG

05/01/2023 10:39

Jan 5 (Reuters) - MORPHOSYS AG  MORG.DE :
    * MORPHOSYS AG REPORTS PRELIMINARY 2022 MONJUVI U.S. NET
PRODUCT
SALES, PROVIDES 2023 FINANCIAL GUIDANCE AND REDUCES FINANCIAL
LIABILITY
    * PRELIMINARY 2022 MONJUVI U.S. NET PRODUCT SALES OF US$
89.4
MILLION (EUR 84.9 MILLION)
    * PRELIMINARY UNAUDITED FINANCIAL LIABILITY FROM
COLLABORATION
WITH INCYTE OF APPROXIMATELY EUR 220 MILLION WHICH REPRESENTS A
REDUCTION OF EUR 360 MILLION
    * ANTICIPATED 2023 MONJUVI U.S. NET PRODUCT SALES IN RANGE
OF US$
80 TO 95 MILLION
    * SEES 2023 RESEARCH AND DEVELOPMENT EXPENSES EUR 290M TO
315M
    * SEES 2023 SG&A EXPENSES EUR 140M TO 155M

Further company coverage:  MORG.DE 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))